CYNORA
Marking a new innovation trajectory for the OLED industry, CYNORA today announced that device test kits for its Thermally Activated Delayed Fluorescence (TADF)-based Deep Green emitter for next-generation OLED displays are now available to customers. The development is an industry-first milestone for TADF technology, and validates CYNORA’s roadmap commitment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210119006159/en/
Known as the cyUltimateGreen™, the product delivers efficiency of more than 20 percent, which meets current industry specifications of 150cd/A in top emission devices. It demonstrates lifetime of 400h LT95@15mA, and color point and spectra that match today’s DCI-P3 standard. In addition, the product shows compatibility with BT2020, a color standard that requires greater color purity than DCI-P3, and one that will significantly enlarge the color depth.
The milestone delivers a materials technology breakthrough that will help display manufacturers unleash the full efficiency potential of new-generation OLEDs and catalyze game-changing OLED products. It starts with TADF Deep Green and will soon include a TADF Deep Blue solution.
The cyUltimateGreen Emitter: A “Brightness” Booster for Next-Generation OLEDs
Within the OLED stack is the emissive layer. This is where the light is made. Within the layer are Red, Green and Blue pixels. By combining all three, the full color gamut is rendered in the display. The Green pixel influences brightness. It accounts for as much as 25 percent of the OLED stack costs.
CYNORA’s CEO, Adam Kablanian, commented: “We set out to innovate a differentiated new technology that would enable display leaders to leapfrog beyond legacy emitter solutions for next-generation OLEDs. We believed that TADF was the most promising approach. We knew that with the right blend of advanced technologies and chemistry expertise, the breakthrough was achievable. Our talented team has confirmed the commercial capability of the TADF emitter technology, which has the ability to offer customers substantial savings. The kits are now ready for customer testing and verification.”
GEM: CYNORA’s Materials Discovery Advantage
Behind the cyUltimateGreen product is CYNORA’s Generative Exploration Model (GEM). GEM is the materials discovery engine pioneered by CYNORA to identify with extreme precision the most relevant and useful molecules, and related combinations, from an infinite source of chemical molecules.
GEM combines two key elements: artificial intelligence (AI) and the brainpower of CYNORA’s chemists. While AI offers immense computational capabilities, there can be prediction errors and other uncertainties that diminish the output of useful data for specialized applications. GEM supercharges AI for OLED materials discovery by pairing its computing power with the materials expertise and OLED device knowledge of CYNORA’s chemists to identify molecules with high potential. From there, a scoring system predicts how closely the molecule conforms to must-have parameters, as well as its usefulness for the target purpose – in this case, high-efficiency emitter materials.
GEM strengthened CYNORA’s discovery and synthesis capabilities, and fast-tracked completion of the cyUltimateGreen product, said CTO, Dr. Jan Richter. “Given that the universe of chemical molecules is infinite, identifying the most relevant molecules is exceedingly tough,” he said. “While AI gives us a powerful discovery acceleration tool, our imperative isn’t just to find molecules that are a theoretical fit; they must also be chemically synthesizable. That’s where CYNORA’s chemistry expertise provides the value add.”
The expertise extends to CYNORA technologists’ deep knowledge of the full OLED device. This helped the company engineer the cyUltimateGreen to meet mass-production requirements, without requiring display leaders to make expensive alterations to their manufacturing lines. Essential details like matching evaporation temperatures to meet current device architectures, and aligning material parameters (like energy levels), were part of the calculations. To further reduce cost, integration factors were also considered, like how to manufacture the product within existing hardware and process frameworks without requiring extra evaporation chambers.
Richter added: “TADF technology is igniting a new innovation trajectory for OLED emitter materials. We’re excited to lead with our cyUltimateGreen product.”
For information on CYNORA GmbH, please visit www.cynora.com
cyUltimateGreen is a trademark of CYNORA GmbH
View source version on businesswire.com: https://www.businesswire.com/news/home/20210119006159/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
